Johns Hopkins to ban gifts, drug samples

Share this article:

Johns Hopkins announced the approval of a policy that will severely limit industry interaction with its school of medicine.

Industry-funded meals, drug samples and gifts to individuals will be off limits to Johns Hopkins faculty and staff under the policy, effective July 1, 2009. The drug sample provision will become effective next year – on July 1, 2010 – so that “affected providers and clinics can make the needed changes,” according to the policy.

“Gifts, even small gifts, carry an implied expectation of reciprocity,” the policy stated. “Accepting a coffee mug or mouse pad from a pharmaceutical sales representative may not consciously affect one's decision-making,” but the presence of the gift, or the interaction with the giver, could cloud a physician's judgment, the policy concluded, citing research from the Annual Review of Neuroscience.

The policy makes an exception for certain unrestricted gifts, which are deposited into a departmental account and distributed at the school's discretion. Departments will be required to report all funds received from industry, and how those funds were spent, the policy stated.

Johns Hopkins' gift ban follows similar initiatives at several other academic institutions, including Stanford and the University of Pittsburgh. The University of Minnesota is currently reviewing a comparable policy.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...